No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer By Ogkologos - August 19, 2025 386 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ASTER 70s study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR New Blood Test Can Screen For Over 50 Cancers June 7, 2021 Combination of Temozolomide and Capecitabine Associated with Improved PFS Compared to... October 24, 2022 Pembrolizumab Demonstrates Robust, Durable Antitumour Activity and Promising Survival in Advanced... July 21, 2021 College Basketball Star Plays First Game in Nearly Two Years After... December 1, 2020 Load more HOT NEWS What People With Breast Cancer and Survivors Should Know About Exercising... FDA Approves Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma Safety Analysis Shows that Durvalumab Treatment After SBRT Is Feasible in... Commemorating the Contributions of Cancer Research Greats
